

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

10/799,286

Filing Date

March 12, 2004

First Named Inventor

Rajagopal Bakthavatchalam

Art Unit

1614

Examiner Name

K. Weddington

Attorney Docket Number

02-090-Z (NEU-02-090-Z)

ENCLOSURES (Check all that apply)

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/
Incomplete ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____

☐ Landscape Table on CD

After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify
below):

Supplemental Modified 1449 Form (3 pages)

Cited References (22 references)

Return Receipt Postcard (1 card)

Remarks

Papers transmitted herewith:

1. Transmittal Form (PTO/SB/21; 1 page; this paper)
2. Fee Transmittal (PTO/SB/17; 1 page; 2 copies)
3. Supplemental Information Disclosure Statement (1 page)
4. Supplemental Modified 1449 Form (3 pages)
5. Cited References (22 references)
6. Return Receipt Postcard (1 card)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Maurice M. Klee, Ph.D.

Signature

Maurice Klee

Printed name

Maurice M. Klee, Ph.D.

Date

10/12/05

Reg. No.

30,399

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Maurice Klee

Typed or printed name


Maurice M. Klee, Ph.D.

Date

10/12/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



[265] Atty Dkt: 02-090-Z (NEU-02-090-Z)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bakthavatchalam et al.
Serial No. : 10/799,286
Filed : March 12, 2004
For : CAPSAICIN RECEPTOR LIGANDS
Examiner : K. Weddington
Group : 1614

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 37 CFR §1.97(c), applicants wish to call the Examiner's attention to the references listed on the Supplemental Modified 1449 Form submitted herewith. Copies of these references are enclosed.

Pursuant to 37 CFR §1.97(c) and 37 CFR §1.17(p), please charge Deposit Account No. 11-1158 in the amount of \$180.00. The Director is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 11-1158.

The Examiner is respectfully requested to initial a copy of the Supplemental Modified 1449 Form and return it to applicants to indicate consideration of the references listed thereon in connection with the prosecution of this application.

Respectfully submitted,

Date: 10/12/05

Maurice Klee

Maurice M. Klee, Ph.D.

Reg. No. 30,399


Attorney for Applicant

1951 Burr Street

Fairfield, CT 06824

(203) 255-1400

10/18/2005 MBIZUNES 00000013 111158 10799286
01 FC:1806 180.00 DA



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)
180.00

Complete if Known

Application Number	10/799,286
Filing Date	March 12, 2004
First Named Inventor	Rajagopal Bakthavatchalam
Examiner Name	K. Weddington
Art Unit	1614
Attorney Docket No.	02-090-Z (NEU-02-090-Z)

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____
☒ Deposit Account Deposit Account Number: 11-1158 Deposit Account Name: Maurice M. Klee, Ph.D.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description

Each claim over 20 (including Reissues)

Fee (\$)	Small Entity Fee (\$)
50	25

Each independent claim over 3 (including Reissues)

200	100
-----	-----

Multiple dependent claims

360	180
-----	-----

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 20 or HP =	x	=	

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 3 or HP =	x	=	

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x	=	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Fees Paid (\$)

Other (e.g., late filing surcharge): Pursuant to 37 CFR \$1.97(c) and 37 CFR \$1.17(p)

\$180.00

SUBMITTED BY

Signature	<i>Maurice Klee</i>	Registration No.	30,399	Telephone	(203) 255-1400
Name (Print/Type)	Maurice M. Klee, Ph.D.	(Attorney/Agent)		Date	10/12/05

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



[265] Atty Dkt: 02-090-Z (NEU-02-090-Z)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bakthavatchalam et al.
Serial No. : 10/799,286
Filed : March 12, 2004
For : CAPSAICIN RECEPTOR LIGANDS
Examiner : K. Weddington
Group : 1614

SUPPLEMENTAL MODIFIED 1449 FORM

OTHER ART

Examiner
Initial

- _____ 1. Advertisement for Labsystems' "Fluoroskan Ascent", Nature Biotechnology, back cover, January 1997.
- _____ 2. "The FLIPR® System: Membrane Potential Assays," Retrieved October 6, 2005 from http://www.moleculardevices.com/pages/instruments/flipr_mp.html
- _____ 3. Cortese, Jorge D., "At the Speed of Light: A look at the high-throughput fluorescence laboratory," The Scientist, 2000, 14:18. Retrieved October 6, 2005 from <http://www.the-scientist.com/>
- _____ 4. Golebiowski et al., "Lead compounds discovered from libraries," Current Opinion in Chemical Biology, 2001, 5:273-284.
- _____ 5. Hemmilä et al., "Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications," DDT, 1997, 2:373-381.

- _____ 6. Jerman et al., "Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology," Brit. J. Pharm., 2000, 130:916-922.
- _____ 7. Klopman et al., "Quantitative structure-agonist activity relationship of capsaicin analogues," Journal of Computer-Aided Molecular Design, 1995, 9:283-294.
- _____ 8. Kuntzweiler et al., "Rapid Assessment of Ligand Actions with Nicotinic Acetylcholine Receptors Using Calcium Dynamics and FLIPR," Drug Development Research, 1998, 44:14-20.
- _____ 9. Schroeder et al., "FLIPR: A New Instrument for Accurate, High Throughput Optical Screening," J. Biomolecular Screening, 1996, 1:75-80.
- _____ 10. Silverman et al., "New Assay technologies for high-throughput screening," Current Opinion in Chemical Biology, 1998, 2:397-403.
- _____ 11. Smart et al., "The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)," Brit. J. Pharm., 2000, 129:227-230.
- _____ 12. Szallasi et al., "Identification of Alpha-1-acid Glycoprotein (Orosomucoid) as a Major Vanilloid Binding Protein in Serum," J. Pharmacol. Exp. Therapeutics, 1992, 262:883-888.
- _____ 13. Szallasi et al., "Resiniferatoxin-type phorboid vanilloids display capsaicin-like selectivity at native vanilloid receptors on rat DRG neurons and at the cloned vanilloid receptor VR1," Brit. J. Pharm., 1999, 128:428-434.
- _____ 14. Szallasi et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," Molecular Pharmacology, 1999, 56:581-587.
- _____ 15. Szallasi et al., "Vanilloid (Capsaicin) Receptor in the Rat: Positive Cooperativity of Resiniferatoxin Binding and Its Modulation by Reduction and Oxidation," J. Pharmacol. Exp. Therapeutics, 1993, 266:678-683.

- _____ 16. Tumosa et al., "Fluorescent EIA screening of monoclonal antibodies to cell surface antigens," J. Immun. Methods, 1989, 116:59-63.
- _____ 17. Wahl et al., "Iodo-Resiniferatoxin, a New Potent Vanilloid Receptor Antagonist," Molecular Pharmacology, 2001, 59:9-15.
- _____ 18. Walker et al., "The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain," J. Pharmacol. Exp. Therapeutics, 2003, 304:56-62.
- _____ 19. Walpole et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 1. The Aromatic 'A-Region,'" J. Med. Chem., 1993, 36:2362-2372.
- _____ 20. Walpole et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 2. The Amide Bond 'B-Region,'" J. Med. Chem., 1993, 36:2373-2380.
- _____ 21. Walpole et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 3. The Hydrophobic Side-Chain 'C-Region,'" J. Med. Chem., 1993, 36:2381-2389.
- _____ 22. Wrigglesworth et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 4. Potent, Orally Active Analgesics," J. Med. Chem., 1996, 39:4942-4951.